No profile data available.
Jinxin Fertility Group Limited (1951.HK) is a healthcare company in the focused walk-in medical services industry, based in Chengdu, China, with about 3,128 full-time employees.
It reported revenue of 2.65 billion CNY for fiscal year 2025, down 5.8% from fiscal year 2024, and net income of -976.15 million CNY. Greater China was its largest region in fiscal year 2025, with 77% of revenue. Its market capitalization was 5.77 billion HKD as of October 9, 2026.
Figures from company filings and market data; latest fiscal year ended December 31, 2025; market data as of October 9, 2026.
Jinxin Fertility Group Limited, an investment holding company, provides assisted reproductive services (ARS) in China and internationally.
Jinxin Fertility Group reported 2.65 billion CNY in revenue for fiscal year 2025, down 5.8% from 2.81 billion CNY in fiscal year 2024.
Greater China: 77% of revenue by region in fiscal year 2025, followed by Overseas (23%).
5.77 billion HKD as of October 9, 2026.
Listed companies of a similar size in the same industry (focused walk-in medical services) include Arrail Group Limited (6639.HK), C-mer Medical Holdings Limited (3309.HK), Euroeyes (1846.HK), Meihao Medical Group Co., Ltd (1947.HK).